Clinical evidence for ashwagandha benefits is strongest for stress reduction and sleep quality over eight to twelve weeks. Controlled research shows that results are outcome-specific rather than universal. Findings for anxiety remain unclear, evidence for testosterone is limited, and data for most other health conditions are absent. Documented liver and thyroid risks also require clinical caution before starting.
The Verdict
The Verdict on Ashwagandha Benefits by Health Claim
Controlled trials show a small but statistically significant improvement in stress and sleep, while evidence across other health claims remains weak or unproven.
Published scientific literature tells a narrower story. The botanical demonstrates documented physiological activity in specific areas, but trial quality varies widely across categories.
NCCIH explicitly notes that there is not enough evidence to determine if ashwagandha is helpful for athletic performance, cognitive function, diabetes, asthma, menopause, or female infertility. Furthermore, there is not sufficient high-quality evidence to support its use for COVID-19. Categorizing the herb by individual clinical outcome allows prospective users to weigh documented physiological responses against unverified assertions.
| Health Claim | What the Evidence Shows | Evidence Strength |
|---|---|---|
| Stress and Morning Cortisol | Reduces self-reported stress scores and lowers morning cortisol across randomized trials. | Strongest |
| Sleep Quality and Insomnia | Improves overall sleep quality scores in pooled trial data; actigraphy parameters were measured, but no pooled actigraphy result is reported. | Small effect, low certainty |
| Anxiety Symptoms | Designated unclear by federal health authorities, despite secondary score improvements in sleep trials. | Unclear |
| Testosterone Elevation | Limited evidence suggests increases over two to four months. | Limited |
| Athletic Performance and Muscle Growth | Insufficient evidence to determine whether supplementation improves physical strength or athletic outcomes. | Insufficient |
| Cognitive Function | Insufficient clinical trial evidence to verify improvements in cognitive function. | Insufficient |
| Blood Sugar Regulation and Diabetes | Insufficient clinical evidence to establish glycemic control, paired with documented prescription drug interaction risks. | Insufficient |
| Thyroid Function | No clinical proof of therapeutic benefit for underactive thyroid function. | Insufficient |
Stress and Sleep Quality Evidence in Controlled Trials
Pooled clinical trial data demonstrate that standardized ashwagandha extract produces small but statistically significant improvements in adult sleep quality.
A systematic review and meta-analysis evaluated five randomized controlled trials comprising 400 participants. For overall sleep, the primary outcome yielded a standardized mean difference (SMD) of -0.59, with a 95% confidence interval (CI) from -0.75 to -0.42 and an I² heterogeneity of 62%. In clinical research, an SMD expresses the size of an intervention effect relative to variability. A value near 0.2 represents a small effect, while 0.5 is conventionally read as moderate. The review authors described this primary result as a small but significant effect on overall sleep.
The analysis revealed an important internal tension between subjective assessment scales. On the seven-point Sleep Quality Scale, ashwagandha produced an SMD of -1.16 (95% CI -1.65 to -0.66, I² = 64%), categorized as low-certainty evidence. However, when sleep was assessed using the Pittsburgh Sleep Quality Index, the pooled SMD was -0.90 (95% CI -2.13 to 0.33), which did not achieve statistical significance. Beyond questionnaires, trials monitored objective actigraphy metrics: sleep onset latency, total sleep time, wake time after sleep onset, total time in bed, and sleep efficiency.
Subgroup analyses from the systematic review show who responded best and under what trial conditions. Participants diagnosed with insomnia achieved a larger pooled effect size than healthy adults. Trials testing daily intakes of 600 mg/day or higher yielded greater improvements than lower doses. Interventions running for 8 weeks or longer demonstrated stronger outcomes than shorter trials. No serious side effects were reported in the pooled trial cohorts, though the authors noted that safety data for extended use remain limited.
Measured morning cortisol serves as the primary physiological biomarker with repeated randomized trial evidence behind this botanical. Full trial data, specific extract comparisons, and dosing math are covered in our review of the best cortisol supplement. Readers comparing ashwagandha against alternative sleep aids can evaluate options in our analysis of the best deep sleep supplement.
| Subgroup Category | Pooled Effect Size (SMD) | 95% Confidence Interval | Clinical Context |
|---|---|---|---|
| Insomnia Diagnosis | -0.84 | -1.10 to -0.58 | Larger measured benefit in clinical sleep disturbance |
| Healthy Adults | -0.63 | -0.83 to -0.43 | Moderate improvement in baseline sleep metrics |
| Dose 600 mg/day or Higher | -0.69 | -0.93 to -0.45 | Subgroup cutoff defined by meta-analysis authors |
| Dose Under 600 mg/day | -0.44 | -0.60 to -0.28 | Lower magnitude of sleep metric improvement |
| Duration 8 Weeks or Longer | -0.68 | -0.91 to -0.45 | Extended trial duration shows stronger pooled effect |
| Duration Under 8 Weeks | -0.37 | -0.46 to -0.27 | Shorter intervention periods yield smaller shifts |
Anxiety Findings and Published Evidence Contradictions
Published evidence regarding ashwagandha for anxiety presents a direct conflict between federal agency evaluations and individual trial outcome scores.
NCCIH maintains an explicit position: "However, evidence is unclear about its effects on anxiety." This assessment contrasts with the pooled sleep meta-analysis, where anxiety was evaluated as a secondary outcome. In that pooled calculation, ashwagandha produced a statistically significant mean difference (MD) of -2.19 (95% CI -3.39 to -1.00) across standardized anxiety rating scales.
The gap between trial-level metrics and agency consensus reflects methodological constraints. NCCIH points out that many published studies have relied on small sample sizes and evaluated diverse botanical preparations. For now, NCCIH classifies evidence on anxiety as unclear.
Strength, Athletic Performance, and Cognitive Function Claims
Scientific evidence remains insufficient to confirm that ashwagandha supplementation increases muscular strength, athletic performance, or cognitive capabilities.
NCCIH explicitly states that there is not enough evidence to determine if ashwagandha is helpful for athletic performance or cognitive function.
This position reflects an absence of robust proof rather than definitive negative findings. Existing studies have had small sample sizes and have used a variety of ashwagandha preparations.
Endocrine claims regarding testosterone follow a similarly restricted evidence profile. NCCIH notes that limited evidence suggests taking ashwagandha for 2 to 4 months may increase testosterone levels. However, these findings remain preliminary and are drawn from narrow cohorts. Detailed endocrine trial data and clinical hormone protocols are analyzed in our review of TRT vs testosterone boosters. Because the herb may elevate androgen levels, NCCIH specifically warns that individuals with hormone-sensitive prostate cancer should avoid its use.
Blood Sugar Regulation and Prescription Drug Interactions
Clinical evidence does not support using ashwagandha for diabetes or blood sugar management, while established pharmacologic interactions create direct medical hazards.
NCCIH classifies diabetes among the conditions lacking sufficient evidence to determine efficacy. Supplementing for glycemic control without clinical oversight is unsupported by validated trial literature.
Prescription interactions pose a more serious clinical concern than the absence of glycemic benefit. NCCIH warns that ashwagandha might interact with several medication classes, specifically highlighting drugs for diabetes.
Interaction risks extend beyond diabetes therapies. NCCIH documents that ashwagandha may interact with high blood pressure medicines, immunosuppressants, sedatives, anti-seizure medications, and thyroid hormone medications. Anyone managing chronic medical conditions must account for these documented pharmacologic overlaps.
Evaluating supplement labels requires looking beyond raw milligram figures. A declared milligram weight on a product container is meaningless without identifying the specific extract type and the verified withanolide percentage. How extraction methods determine active compound yields is detailed in our guide to the best cortisol supplement. Assessing compound integrity and excipient listings under federal regulations is covered in our walkthrough on how to read a supplement label.
Realistic Timelines to Notice Ashwagandha Benefits
Clinical trials indicate that measurable physiological responses to ashwagandha require between eight and twelve weeks of consistent daily administration.
Prospective users often expect rapid changes within days of starting supplementation. Published research does not support immediate onset. In the pooled sleep meta-analysis, trials running for 8 weeks or longer achieved an overall sleep SMD of -0.68, whereas interventions lasting under 8 weeks yielded an SMD of only -0.37.
Hormonal outcomes require even longer observation periods. NCCIH notes that limited evidence showing testosterone increases involved administration lasting 2 to 4 months.
Trial timelines establish a clear clinical stopping rule. NCCIH states that ashwagandha may be safe when taken in the short term, defined as up to 3 months. However, the agency warns that there is not enough information to reach conclusions regarding its long-term safety. If an individual does not experience noticeable benefits for sleep or stress by 8 to 12 weeks, continuing use past 3 months introduces uncharacterized safety risks without therapeutic justification.
| Target Outcome | Trial Benchmark Duration | Measured Effect Window | What the Safety Window Is |
|---|---|---|---|
| Sleep Quality | 8 to 12 weeks | Stronger SMD observed after 8 weeks | Trials measured their endpoints at 8 to 12 weeks |
| Stress Reduction | 8 to 12 weeks | Not established | Safety documented only to 3 months; beyond that is uncharacterized due to safety data limits |
| Testosterone Elevation | 2 to 4 months | Limited evidence only, over 2 to 4 months | Safety documented only to 3 months; the 2-to-4-month testosterone evidence runs past that window |
| Cognitive or Athletic Claims | Unproven | No verified clinical onset timeline | No safety data beyond 3 months of use |
Morning or Night Dosing for Ashwagandha Benefits
No clinical trial in the current medical literature directly compares morning administration against evening administration of ashwagandha extract.
NCCIH reports that ashwagandha preparations can cause drowsiness, stomach upset, diarrhea, and vomiting in some individuals. Because drowsiness is an established side effect, taking a dose in the evening or prior to bedtime aligns logically with the sleep outcomes observed in clinical trials. Conversely, individuals taking the herb primarily for daytime stress modulation often opt for morning administration to address daytime symptoms. Prospective users must recognize that these timing routines stem from pragmatic deduction rather than direct comparative trial data.
Documented Liver Injury Patterns and Clinical Evidence
Published medical case series document that ashwagandha supplementation can cause cholestatic and mixed liver injury characterized by severe jaundice and prolonged hyperbilirubinemia.
Clinical registries track serious adverse events. A detailed case series from Iceland and the US Drug-Induced Liver Injury Network documented five patients presenting with liver injury caused by ashwagandha. Three cases presented in Iceland between 2017 and 2018, while two were identified in the United States Drug-Induced Liver Injury Network (DILIN) registry in 2016.
The clinical presentation followed a recognizable pattern across all five patients. The cohort included three men and two women, with a mean age of 43 years (range 21 to 62 years). Jaundice developed after a latency period of 2 to 12 weeks of daily supplement use. Symptoms accompanying the jaundice included nausea, lethargy, severe pruritus (itching), and abdominal discomfort. Initial R ratios ranged from 1.4 to 3.3, establishing a cholestatic or mixed hepatocellular-cholestatic injury pattern.
Laboratory testing demonstrated marked hepatic inflammation across the cohort. Peak alanine aminotransferase (ALT) ranged from 261 to 580 U/L, and peak aspartate aminotransferase (AST) spanned 177 to 334 U/L. Peak alkaline phosphatase (ALP) reached 159 to 279 U/L, while peak total bilirubin reached severe levels between 5.9 and 14.4 mg/dL. International Normalized Ratio (INR) remained stable between 0.9 and 1.1. Pruritus and hyperbilirubinemia were prolonged, lasting between 5 and 20 weeks.
Clinical outcomes required months of medical management. None of the five patients developed acute hepatic failure, no liver transplants were required, and all cases were graded as moderate severity, though one patient was hospitalized. Liver enzymes and bilirubin normalized within 1 to 5 months in four patients, while one patient was lost to clinical follow-up. Daily supplement doses reported on packaging in the Icelandic cases ranged from 450 to 1350 mg per day. Chemical analysis confirmed authentic ashwagandha in available supplement samples, with no heavy metals or secondary toxic compounds detected.
A series of five cases cannot establish an absolute incidence rate or quantify risk per user across the general population. NCCIH corroborates this clinical picture, stating that while liver injury is rare, a number of cases link hepatotoxicity to ashwagandha supplements. Patients evaluating hepatic function can review our clinical guides on interpreting high liver enzymes and assessing a standard hepatic function panel.
| Clinical Parameter | Documented Case Series Findings | Diagnostic Significance |
|---|---|---|
| Cohort Size and Origin | 5 patients (3 Iceland, 2 United States DILIN) | Multi-center clinical documentation |
| Latency to Symptom Onset | 2 to 12 weeks of daily intake | Hepatotoxicity manifests within typical trial windows |
| Primary Clinical Signs | Jaundice, nausea, lethargy, pruritus, abdominal discomfort | Cholestatic presentation across all five cases |
| Peak Total Bilirubin | 5.9 to 14.4 mg/dL | Marked hyperbilirubinemia lasting 5 to 20 weeks |
| Peak Alanine Aminotransferase (ALT) | 261 to 580 U/L | Substantial hepatocellular enzyme release |
| Liver Injury Classification | Initial R ratios 1.4 to 3.3 | Confirmed cholestatic or mixed liver injury |
| Resolution Timeline | Enzymes normalized within 1 to 5 months in 4 cases | Prolonged recovery with zero liver failure cases |
| Supplement Chemical Analysis | Ashwagandha confirmed; no metals or adulterants found | No adulterant or metal identified in the samples tested |
Contraindications and Populations Who Should Avoid Ashwagandha
Federal health authorities advise several patient populations to completely avoid ashwagandha due to pregnancy risks, endocrine interactions, and surgical hazards.
NCCIH outlines explicit contraindications based on pharmacological safety data. First, the agency states that ashwagandha should be avoided during pregnancy and must not be used while breastfeeding. Second, the botanical is not recommended for individuals scheduled for surgical procedures. Third, people diagnosed with autoimmune disorders should avoid the herb.
Thyroid conditions represent another critical contraindication. NCCIH warns that ashwagandha is not recommended for those who have thyroid disorders. The botanical does not have clinical evidence supporting its use for hypothyroidism. Patients with thyroid concerns should review our guide to the best cortisol supplement and our clinical overview of the TSH blood test.
Oncology and general tolerability factors round out the contraindication list. Because ashwagandha may elevate androgen levels, NCCIH explicitly states that people with hormone-sensitive prostate cancer should avoid its use. For the general population, milder side effects can include drowsiness, stomach upset, diarrhea, and vomiting. Any prospective user with preexisting health conditions must review these restrictions before starting.
Evidence-Based Evaluation for Prospective Supplement Users
Deciding whether to take ashwagandha requires balancing modest improvements in sleep quality against documented hepatotoxic risks and a three-month safety ceiling.
Ashwagandha is not appropriate for individuals seeking treatment for anxiety disorders, diabetes, or athletic performance deficits. Trial evidence does not support its use for those indications. Furthermore, anyone taking prescription sedatives, blood glucose-lowering drugs, blood pressure medications, immunosuppressants, or thyroid hormones should avoid this botanical due to documented interaction risks.
Our verdict would flip if multi-center randomized controlled trials demonstrate consistent clinical improvements in anxiety scores or metabolic markers using standardized extracts over durations exceeding six months, supported by rigorous hepatic safety monitoring.
To proceed safely, review label verifications by comparing standards in our guide to NSF vs USP verified seals.
Frequently Asked Questions
What does ashwagandha actually do?
Ashwagandha (Withania somnifera) is a botanical extract that modulates physiological stress responses and improves specific sleep parameters. In randomized controlled trials, daily supplementation demonstrated small but statistically significant improvements in adult sleep quality and self-reported stress. However, according to the National Center for Complementary and Integrative Health (NCCIH), there is insufficient evidence to determine if ashwagandha improves athletic performance, cognitive function, diabetes, or female infertility. Furthermore, evidence regarding its effects on anxiety remains unclear.
Are ashwagandha's benefits proven?
Scientific verification of ashwagandha benefits depends entirely on the specific health condition evaluated. Evidence is strongest for insomnia and stress management, where pooled clinical trials show small to moderate improvements in sleep quality. Conversely, claims regarding anxiety, muscle growth, endurance, and blood sugar control are not proven. NCCIH explicitly notes that many studies have had small sample sizes and evaluated diverse botanical preparations, meaning high-certainty conclusions cannot be made across most marketed uses. In addition, short-term safety is documented only up to three months, with long-term safety data remaining unavailable.
How long does ashwagandha take to work?
Clinical trials demonstrate that ashwagandha requires between 8 and 12 weeks of daily administration to produce measurable benefits. In a meta-analysis of sleep trials, studies running for 8 weeks or longer demonstrated an effect size of -0.68, compared to -0.37 for trials lasting under 8 weeks. For hormonal outcomes, NCCIH identifies limited evidence showing testosterone increases over 2 to 4 months. Because NCCIH cautions that safety data beyond 3 months are lacking, for a user who notices no change in stress or sleep quality within 8 to 12 weeks, continuing use past 3 months introduces uncharacterized safety risks for no documented return.
Does ashwagandha help anxiety?
Evidence regarding ashwagandha's effectiveness for anxiety remains officially unclear. While a systematic review of sleep trials reported a secondary reduction in anxiety scores (mean difference -2.19), NCCIH concludes that clinical evidence is unclear regarding its effects on anxiety disorders. This divergence exists because individual trials have involved small participant numbers, disparate botanical extracts, and brief study durations.
Does ashwagandha improve sleep?
Ashwagandha improves overall sleep quality based on pooled clinical trial data. A systematic review analyzing 5 randomized controlled trials and 400 participants found a small but statistically significant improvement in overall sleep (standardized mean difference -0.59). Subgroup data revealed stronger effects in individuals diagnosed with insomnia (-0.84) compared to healthy adults (-0.63). Trials utilizing daily doses of 600 mg/day or higher and durations of 8 weeks or longer also demonstrated superior outcomes.
Does ashwagandha build muscle or improve athletic performance?
Current scientific literature does not support claims that ashwagandha builds muscle or enhances athletic performance. NCCIH explicitly states that there is not enough evidence to determine if ashwagandha is helpful for athletic performance. Existing human trials are small, methodologically variable, and insufficient to verify real-world efficacy. Regarding hormones, NCCIH notes limited evidence suggesting supplementation for 2 to 4 months may increase testosterone levels, but these data remain constrained by small cohorts and have not translated into proven athletic gains.
Should ashwagandha be taken in the morning or at night?
No published clinical trial directly compares morning administration against evening administration of ashwagandha. Supplement timing is therefore guided by the targeted outcome and the botanical's side effect profile. Because drowsiness is an established side effect noted by NCCIH, taking a dose in the evening or before bedtime aligns logically with trial data on sleep quality and insomnia. Individuals using the herb for daytime stress modulation often choose morning administration, though no trial settles the timing. Users should assess personal daytime alertness before deciding on morning versus evening dosing.
Can ashwagandha damage your liver?
Ashwagandha can cause liver injury, although documented cases are rare. A published medical case series from Iceland and the US Drug-Induced Liver Injury Network documented five patients who developed liver injury after taking ashwagandha supplements for 2 to 12 weeks. All five presented with jaundice, nausea, lethargy, severe itching, and marked elevations in liver enzymes and bilirubin. Symptoms took 5 to 20 weeks to resolve, though no patient developed liver failure. Chemical testing confirmed authentic ashwagandha without heavy metal contaminants. NCCIH confirms that a number of cases link liver injury to ashwagandha.
Who should avoid ashwagandha?
NCCIH states that ashwagandha should be avoided during pregnancy and must not be used while breastfeeding. It is not recommended for individuals scheduled for surgery, nor for those with autoimmune disorders or thyroid disorders. Because the botanical may increase testosterone levels, people with hormone-sensitive prostate cancer should also avoid its use. Furthermore, ashwagandha carries documented interaction risks with diabetes medications, high blood pressure drugs, immunosuppressants, sedatives, anti-seizure medications, and thyroid hormone treatments. Anyone taking these prescription medications should avoid the supplement.